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ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a destructive disease in part resulting from 
premature or mature cellular aging. Protease-activated receptor-1 (PAR-1) recently 
emerged as a critical component in the context of fibrotic lung diseases. Therefore, 
we aimed to study the role of macrophages in PAR-1-mediated idiopathic pulmonary 
fibrosis. The number of macrophages were significantly reduced in lungs of PAR-1 
antagonist (P1pal-12) treated animals upon bleomycin instillation. In line with these 
data, PAR-1 stimulation increased monocyte / macrophage recruitment in response 
to epithelium injury in in vitro trans-well assays. Moreover, macrophages induced 
fibroblasts migration, differentiation and secretion of collagen, which were inhibited 
in the presence of TGF-β receptor inhibitors. Interestingly, these profibrotic effects 
were partially inhibited by treatment with the PAR-1 inhibitor P1pal-12. Using shRNA 
mediated PAR-1 knock down in fibroblasts, we demonstrate that fibroblast PAR-1 
contributes to TGF-β activation and production. Finally, we show that the macrophage-
dependent induction of PAR-1 driven TGF-β activation was mediated by FXa. Our 
data identify novel mechanisms by which PAR-1 stimulation on different cell types 
can contribute to IPF and identify macrophages as key players in PAR-1 dependent 
development of this devastating disease. IPF may result from cellular senescence 
mediated by macrophages in the lung.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a devastating 
aging disease characterized by (myo)fibroblast 
proliferation and excessive extracellular matrix (ECM) 
formation leading to destruction of the lung architecture 
in part as a result of premature or mature cell function 
reduction [1-5]. The current paradigm proposes that 
pulmonary fibrosis results from chronic epithelial damage 
leading to an aberrant wound healing response [6-7]. 
Although knowledge of the pathogenesis of IPF continues 
to evolve, therapeutics that effectively improve the clinical 
outcome of IPF are limited [8]. To date, only pirfenidone 
and nintedanib delay the destruction of lung function in 
patients with IPF. However, both drugs have side effects, 
have no effect on the quality of life, and do not stop nor 
reverse the disease [9-11]. This indicates that alternative 
therapeutics are essential for this cell age-related disorder 
and novel treatment options will only become available 
due to the comprehensive understanding of the underlying 
mechanisms like premature/mature cellular senescence 
in the development of IPF. Also, the discovery of 
components involved in premature and mature aging may 
help to prevent premature cellular senescence and restore 
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its regulated function thereby preventing premature lung 
aging [9].
Protease-activated receptor (PAR)-1 is a cell 
surface seven-transmembrane G protein-coupled receptor 
that is activated by proteolytic cleavage, inducing 
transmembrane signaling to intracellular G proteins 
leading to a broad range of pathophysiological pathways 
[12]. Importantly, PAR-1 recently emerged as a critical 
component in the context of fibrotic lung disease. Indeed, 
PAR-1 expression is increased within fibroproliferative 
and inflammatory foci in IPF [13]. PAR-1 activation also 
stimulates fibroblast differentiation and ECM production 
[14, 15]. Moreover, PAR-1 seems to synergize with PAR-3 
to mediate epithelial-mesenchymal transition of alveolar 
epithelial cells [16]. In line with these in vitro data, PAR-1 
deficiency in mice limits bleomycin-induced pulmonary 
fibrosis whereas pharmacological inhibition of PAR-1 also 
limits bleomycin-induced pulmonary fibrosis [13, 14]. 
Interestingly, PAR-1 overexpression is found in 
alveolar macrophages from patients with chronic airway 
disease and PAR-1 expression in IPF patients is associated 
with macrophages [13, 17]. This may be particularly 
important as macrophages are known to be key regulators 
in the progression of pulmonary fibrosis [18-20]. In this 
context, macrophage influx is an early event following 
lung injury and macrophages secrete large amounts of 
profibrotic cytokines like transforming growth factor-β 
(TGF-β) [21]. TGF-β on its turn induces fibroblast 
proliferation and differentiation into myofibroblasts 
leading to ECM deposition thereby promoting fibrosis 
[20]. 
In the present study, we aimed to address the 
potential importance of macrophages in PAR-1-dependent 
pulmonary fibrosis. We show that PAR-1 modifies 
macrophage recruitment to the lung during pulmonary 
fibrosis, and we identify a potential mechanism by 
which PAR-1 mediates macrophage induced profibrotic 
responses.
RESULTS
PAR-1 regulates monocyte / macrophage 
recruitment during pulmonary fibrosis
As macrophage recruitment in response to 
chemoattractant production by injured epithelial cells 
is a key process in fibrosis, we set out to determine 
whether PAR-1 would modify macrophage recruitment 
into fibrotic lungs. As shown in Figure 1A, macrophages 
were omnipresent in lungs of wild type mice subjected 
to bleomycin-induced pulmonary fibrosis as evident 
from large amounts of F4/80 (ADGRE1) positive cells. 
Interestingly, macrophage numbers were reduced by 
approximately 50% in fibrotic mice treated with the PAR-
1 inhibitor P1pal-12 (Figure 1B, 1C). 
To assess whether the reduced macrophage numbers 
in P1pal-12 treated mice are due to a direct effect of 
PAR-1 on the migration of macrophages towards injured 
epithelium, the migration of RAW264.7 macrophages 
was measured in vitro. To mimic the in vivo setting, 
Figure 1: PAR-1 inhibition reduces macrophage numbers in the lung of bleomycin treated mice. Representative macrophage 
marker F4/80 stained sections obtained 14 days after bleomycin instillation in wild type mice A. and wild type mice treated with the PAR-
1 inhibitor P1pal-12 (2.5 mg/kg) B. The arrows indicate an example of F4/80 positive macrophages. C. Quantification of macrophage 
numbers in fibrotic mice treated or not with P1pal-12 (mean±SEM, n = 8 mice per group). *P < 0.05.
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lung epithelial cells were exposed to bleomycin (10 μg/
ml) for 48 or 72 hours after which the medium was used 
as chemoattractant for RAW264.7 cells. As shown in 
Figure 2A, medium of bleomycin-exposed MLE-15 cells 
indeed served as a chemoattractant for RAW264.7 cells. 
Stimulation of RAW264.7 cells with the PAR-1 agonist 
thrombin did not have any effect on migration towards 
control medium, but potentiated migration towards 
bleomycin-treated MLE-15 conditioned medium (Figure 
2B-2D). These results thus indicate that macrophage 
recruitment into injured lungs seems (at least in part) PAR-
1 dependent.
Macrophages induce fibrotic responses in 
fibroblasts via TGF-β in a PAR-1 dependent 
manner
To assess whether the decreased number of 
macrophages in lungs of P1pal-12 treated mice correlate 
with the observed reduction in fibrosis, we subsequently 
analyzed macrophage-induced profibrotic responses in 
fibroblasts. RAW264.7 conditioned medium induced 
fibroblast migration as demonstrated by efficient wound 
closure which is not observed in the control medium 
(Figure 3A-3B). In line, RAW264.7 conditioned medium 
Figure 2: PAR-1 regulates macrophages migration in trans-well assays. A. Migration of RAW264.7 cells towards epithelial 
cell conditioned medium (collected after exposure to 10 μg/ml bleomycin for 48 or 72 hours) for 10 hours. RAW264.7 cell migration 
towards plain medium was used as control. B. Migration of RAW264.7 cells towards control or MLE-15 conditioned medium (10 μg/ml 
bleomycin for 72 hours) for 10 hours in the absence or presence of thrombin (1 U/ml). Shown is the mean ± SEM, n = 3. C. Representative 
pictures of RAW264.7 cells migrated through the trans-well toward plain control or MLE-15 epithelial cells conditioned medium (CM) 
stimulated with or without thrombin (1 U/ml). D. Quantification of the data presented in C. (mean ± SEM of an experiment performed three 
times, *P < 0.05 and **P < 0.01).
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also induced fibroblast differentiation and ECM production 
as evident from increased alpha-smooth muscle actin 
(α-SMA; ACTA2) and collagen I expression levels (Figure 
3C). To determine whether the macrophage-induced 
profibrotic responses of fibroblasts rely upon PAR-1 
activation on fibroblasts, we next pre-incubated fibroblasts 
with P1pal-12 before assessing the macrophage-dependent 
fibrotic responses. As shown in Figure 3, P1pal-12 
treatment significantly inhibited macrophage-induced 
wound closure, fibroblast differentiation and collagen 
deposition suggesting macrophages potentiate fibroblast-
driven fibrosis in a PAR-1 dependent manner. 
Next, we determined whether TGF-β plays a 
dominant role in the pro-fibrotic effects of RAW264.7 
conditioned medium. We assessed macrophage-dependent 
fibroblast migration in the presence of TGF-β receptor 
inhibitors. As shown in Figure 3A-3B, inhibition of TGF-β 
signaling inhibited RAW264.7 conditioned medium-
induced wound closure. Consistently, TGF-β receptor 
(TGFBR) inhibition also prevented macrophage-induced 
fibroblast differentiation (i.e. α-SMA expression) and 
ECM deposition (i.e. collagen production) (Figure 3). 
Figure 3: Macrophages-induced fibrotic responses of fibroblasts are PAR-1 dependent. A. Wound size of NIH3T3 fibroblast 
monolayers after treatment with PBS (control) or RAW264.7 conditioned medium (CM) for 18 hours in the presence or absence of TGFBR 
inhibitors (10 μM SB-431542 and 10 μM LY-2157299) or P1pal-12 (10 μM). Shown are photographs of representative microscopic fields. 
B. Quantification of the results depicted in A. as described in the Materials and Methods section. Data are expressed as mean±SEM (n 
= 6 independent experiments). ***P < 0.001. C. Western blot analysis of α-SMA and collagen expression in NIH3T3 cells stimulated 
with RAW264.7 CM in the absence or presence of P1pal-12 (10 μM) or TGFBR inhibitors (10 μM of SB-431542 and 10 μM of LY-
2157299). Tubulin served as loading control. Gels have been run under the same experimental conditions and uncropped blots are shown 
in Supplementary Figure.
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To confirm these findings, we assessed macrophage-
induced SMAD2 phosphorylation, a direct downstream 
target of TGFBR activation in fibroblasts. As shown in 
Figure 4A, RAW264.7 conditioned medium clearly caused 
a time-dependent increase in SMAD2 phosphorylation 
in fibroblasts. Notably, SMAD2 phosphorylation was 
completely blocked by TGF-β receptor inhibitors. SMAD2 
phosphorylation was also partly blocked by the PAR-1 
inhibitor P1pal-12. This suggests that TGF-β signaling on 
fibroblasts is in part mediated by PAR-1.
To evaluate the P1pal-12 data and to elucidate the 
mechanism by which PAR-1 influences TGF-β signaling, 
we generated a stable PAR-1 knockdown fibroblast cell 
line. As shown in Figure 4B, fibroblasts lentivirally 
transduced with PAR-1 shRNA (indicated as PAR-1-
/- cells) proliferated to a similar extent as fibroblasts 
transduced with control shRNA (indicated as WT cells). 
However, the PAR-1-/- cells did not respond to thrombin 
stimulation in calcium assays as opposed to wildtype 
(WT) cells confirming efficient knock-down (Figure 4C). 
As expected, WT fibroblasts showed increased SMAD2 
phosphorylation after stimulation with RAW264.7 
conditioned medium (Figure 4D). In line with p1pal-12 
treatment, PAR-1 knock-down significantly inhibited 
macrophage-induced SMAD2 phosphorylation (Figure 
4D). Notably, PAR-1-/- fibroblasts still responded to direct 
TGF-β stimulation and showed similar SMAD2 levels as 
WT fibroblasts (Figure 4D). Our data thus show that PAR-
1 on fibroblasts modifies TGF-β signaling most likely by 
regulating the activation of latent TGF-β. 
Finally, we assessed whether fibroblast PAR-
1 would also modify TGF-β production induced by 
macrophage-conditioned medium. As shown in Figure 
4E, baseline latent TGF-β levels were already reduced 
in PAR-1-/- fibroblasts as compared to WT fibroblasts. 
Moreover, RAW264.7 conditioned medium induced 
TGF-β expression by WT cells but not by PAR-1-/- cells 
(TGF-β level in PAR1-/- cells stimulated with RAW264.7 
Figure 4: PAR-1 mediates TGF-β activation and production. A. Representative Western blot analysis of SMAD2 phosphorylation 
in NIH3T3 cells stimulated for 0, 15, 30 and 60 minutes with RAW264.7 CM in the absence or presence of TGFBR inhibitors (10 μM 
SB-431542 and 10 μM LY-2157299) or P1pal-12 (10 μM). GAPDH served as loading control. B. Cell viability of NIH3T3s lentivirally 
transduced with a control shRNA construct (WT fibroblasts, down-pointing triangle) or a PAR-1 shRNA construct (PAR-1-/- fibroblasts, 
up-pointing triangle) as evaluated by MTT assays after 12 or 24 hours of incubation (Mean+/-SEM of an experiment performed two times 
in octoplo). C. Intracellular Ca2+ fluxes in WT fibroblasts (circle) and PAR-1-/- fibroblasts (square) after stimulation with thrombin (1 U/
ml). Ca2+ fluxes are expressed as arbitrary units of fluorescent intensity after background correction. Shown is a representative experiment 
of three independent experiments. D. Western blot analysis of SMAD2 phosphorylation in WT fibroblasts or PAR-1-/- fibroblasts stimulated 
for 0, 15, 30 and 60 minutes with RAW264.7 CM or recombinant TGF-β (1 ng/ml). GAPDH served as loading control. E. Total TGF-β 
production of RAW264.7 cells and WT or PAR-1-/- fibroblasts stimulated without or with RAW264.7 conditioned medium (CM) after 24 
hours (mean ± SEM, n = 6; ***P < 0.001). 
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conditioned is similar to the levels in conditioned medium 
alone). It seems that PAR-1 expression on fibroblasts also 
potentiates TGF-β production.
Factor Xa as PAR-1 agonist secreted by 
RAW264.7 cells
The data obtained suggest a crosstalk between 
fibroblasts and macrophages, where macrophages 
are a source of one or several PAR-1 agonist(s) that 
subsequently stimulate fibroblasts leading to TGF-β 
production and activation. Hence, to identify the 
potential PAR-1 agonist, we first analyzed mRNA 
levels of known PAR-1 agonists in RAW264.7 cells. 
Interestingly, Granzyme K and particularly factor X (FX) 
are significantly expressed by RAW264.7 macrophages, 
whereas matrix metallopeptidase (MMP)-1, kallikrein 
(KLK)-1, -4 and -6 were expressed at relatively low levels. 
To prove or refute that FX is the PAR-1 agonist secreted 
by RAW264.7 cells, we next determined RAW264.7 
cell-induced TGF-β signaling by assessing SMAD2 
phosphorylation in fibroblasts in the absence or presence 
of antistasin, a direct FXa inhibitor. As shown in Figure 
5B, RAW264.7 conditioned medium-induced SMAD2 
phosphorylation was almost completely blocked by 
antistasin pinpointing FXa as endogenous PAR-1 ligand 
secreted by Raw264.7 cells.
DISCUSSION
Cell function reduction is considered as a hallmark 
of cell aging, which is classified into either premature 
or mature cell aging. During premature and mature 
cellular senescence, IPF may occur. Epidemiological 
and biological studies suggest that IPF is an aging-
related disease [2, 22-24]. There is compelling evidence 
that PAR-1 plays an important role in mediating pro-
fibrotic effects and pharmacological inhibition of PAR-1 
limits bleomycin-induced pulmonary fibrosis [13-15]. 
The underlying mechanism by which PAR-1 modulates 
pulmonary fibrosis is however not yet fully understood. 
In the current manuscript, we identify macrophages as 
key players in PAR-1 driven pulmonary fibrosis. We 
show that PAR-1 on macrophage potentiates recruitment 
of macrophages towards injured lung epithelial cells. 
Recruited macrophages subsequently secrete PAR-
1 agonists that stimulate fibroblasts to produce and 
activate latent TGF-β leading to fibroblast migration, 
differentiation into myofibroblasts and ECM deposition 
(Figure 5C).
A key finding of our study is the fact that 
macrophage numbers are significantly reduced in fibrotic 
lungs as a consequence of pharmacological PAR-1 
inhibition. To evaluate whether PAR-1 directly modifies 
macrophage migration, we simulated the in vivo condition 
by analyzing macrophage migration towards conditioned 
medium obtained from bleomycin-treated lung epithelial 
Figure 5: PAR-1-induced TGF-β activation on fibroblasts is mediated by FX. A. Thrombin (FII), FX, Granzyme K (GZMK), 
MMP1, MMP13, KLK1, KLK4 and KLK6 mRNA levels in RAW264.7 cells as assessed by real-time reverse transcriptase PCR. Data are 
expressed relative to two housekeeping genes, GAPDH and TBP. Shown is the mean ± SEM, of an experiment performed three times. 
B. Western blot analysis of SMAD2 phosphorylation in NIH3T3 cells stimulated for 0, 15, 30 and 60 minutes with RAW264.7 CM in 
the absence or presence of the FXa inhibitor antistasin (40 μM). GAPDH served as loading control. C. Proposed mechanism by which 
macrophages promote lung fibrosis in a PAR-1 dependent manner. During lung injury, epithelial cells release mediators that potentiate 
PAR-1 dependent macrophage migration towards the injured site (1). The recruited macrophages subsequently secrete TGF-β and FX. The 
PAR-1 agonist (FX) than activates PAR-1 on fibroblasts (2) leading to TGF-β production and activation. Finally, TGF-β induces TGFBR 
signaling (3) on fibroblast thereby inducing their migration, differentiation and ECM deposition.
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cells in trans-well assays. Interestingly, PAR-1 activation 
by thrombin did not affect macrophage migration towards 
control medium, but did potentiate directed migration 
towards conditioned medium of injured epithelial 
cells. This suggests that PAR-1 specifically modifies 
chemotaxis of macrophages in the setting of pulmonary 
fibrosis. The underlying mechanism by which PAR-1 
modifies chemotaxis remains unclear although a recent 
study elegantly shows that PAR-1 activation by thrombin 
on human monocytes (THP-1 cells) leads to cytoskeletal 
remodeling and migration [25].
Macrophages recruited to injured lung tissue 
contribute to the development of fibrosis by secreting the 
profibrotic cytokine TGF-β that, once activated, targets 
fibroblasts [18-21]. Our study shows that macrophage 
TGF-β induces fibroblast migration, differentiation and 
ECM deposition. Of note, macrophages-induced pro-
fibrotic responses were inhibited by a TGFBR blocking 
cocktail, resulting in inactivation of both TGF-β 
receptor I (TGFBRI) and II (TGFBRII). Interestingly, all 
macrophage conditioned medium-induced pro-fibrotic 
responses were also partially inhibited by the specific 
PAR-1 inhibitor P1pal-12 which may suggest that PAR-
1 directly regulates TGF-β receptor signaling. However, 
TGF-β is still efficiently triggering TGF-β receptor 
dependent Smad2 phosphorylation in PAR-1 knock down 
cells. This suggests that PAR-1 is not required when 
TGF-β is activated. Most likely, PAR-1 contributes to 
TGF-β activation on fibroblasts and indeed thrombin-
dependent PAR-1 cleavage leads to TGF-β activation 
on respiratory epithelial cells [26]. It seems that PAR-1 
activation induces actin polymerization with subsequent 
conformational changes in the integrin/latent TGF-β 
complex that allows the interaction between active TGF-β 
and its adjacent receptors [27, 28]. Additionally, blocking 
integrin signaling inhibited TGF-β activation during acute 
lung injury, confirming the importance of this PAR-1-
dependent TGF-β activation pathway in vivo [26].
Our data show that macrophage conditioned medium 
contains a PAR-1 ligand leading to PAR-1 dependent 
activation of latent TGF-β. We identified FXa as the 
most likely endogenous agonist secreted by macrophages 
(consistent with the previous study [29]) based on our data 
showing that a specific FXa inhibitor blocked macrophage 
conditioned medium-induced TGF-β signaling. Notably, 
FXa plays an important role in the pathogenesis of 
pulmonary fibrosis via enhancement of TGF-β activation 
in a PAR-1 and integrin-dependent manner. In this regard, 
FXa inhibition limited bleomycin-induced pulmonary 
fibrosis [30]. In addition to FXa, other PAR-1 agonists 
may also be able to contribute to TGF-β activation. 
Macrophages also express relatively high mRNA levels of 
Granzyme K, known to induce pro-inflammatory cytokine 
secretion and lung fibroblast proliferation through PAR-
1 [31]. Although all other potential PAR-1 agonists only 
showed low expression levels in RAW264.7 cells in our 
experiments, these proteases may obviously not be ruled 
out as key players in PAR-1 driven pulmonary fibrosis. 
Intriguingly, PAR-1 appeared to be important for 
TGF-β secretion by fibroblasts. Although fibroblasts 
produce relatively low levels of latent TGF-β as compared 
to macrophages, PAR-1 knock down fibroblasts produced 
significantly less latent TGF-β than PAR-1 expressing 
fibroblasts in unstimulated conditions. This suggests 
that PAR-1 may actually be essential for fibroblasts to 
secrete latent TGF-β. Moreover, fibroblast stimulation 
by macrophages conditioned medium (containing PAR-1 
agonists as discussed above) induced secretion of latent 
TGF-β in wild type but not PAR-1 knock down fibroblasts. 
Our data confirm previous findings that activation of PARs 
may indeed lead to cytokine release and TGF-β production 
[32-33]. The role of PAR-1 in TGF-β expression by 
fibroblasts and the potential effect of fibroblast TGF-β in 
pulmonary fibrosis remains to be elucidated. 
In conclusion, PAR-1 stimulation on different 
cell types may contribute to pulmonary fibrosis and we 
propose a PAR-1-mediated pathogenesis of pulmonary 
fibrosis (Figure 5C). We show that macrophages play a 
crucial role in PAR-1 dependent pulmonary fibrosis and 
we suggest that macrophages secrete FXa that targets 
fibroblasts to enhance TGF-β driven fibrotic effects.
MATERIALS AND METHODS
Reagents
Thrombin and bleomycin were from Sigma (St-
Louis, MO), recombinant TGF-β was from Tebu-bio 
(Heerhugowaard, Netherlands), the specific FXa inhibitor 
antistasin-related peptide was purchased from Bachem 
(Bubendorf, Switzerland), TGFBRI and TGFBRII were 
inhibited by a combination of inhibitors SB-431542 
and LY-2157299, which were from Axon medchem 
(Groningen, Netherlands) whereas PAR-1 inhibitor 
P1pal-12 (palmitate-RCLSSSAVANRS-NH2) was from 
GL Biochem Ltd (Shanghai, China). 
Cell lines and conditioned medium preparation
Murine NIH3T3 fibroblasts and RAW264.7 
macrophages were cultured in DMEM and IMDM, 
respectively, supplemented with 10% fetal calf serum 
(FCS). Murine lung epithelial cells (MLE-15) were 
cultured in HITES medium (RPMI supplemented with 
5 µg/ml insulin, 10 µg/ml transferrin, 10 nM estradiol 
and 10 nM hydrocortisone). Cells were grown at 37°C in 
an atmosphere of 5% CO
2
. Unless indicated otherwise, 
cells were washed twice with PBS and serum-starved 
for 4 hours before stimulation. For conditioned medium 
preparations, cells were seeded and grown overnight under 
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normal growth conditions to reach subconfluency. Next, 
the cells were washed with PBS and incubated for 24 
hours in FCS free medium with or without the indicated 
agonists. Finally, the collected media were centrifuged, put 
through a 0.2 µm filter and stored at -20 oC.
Animal model of pulmonary fibrosis
Ten-week-old C57Bl/6 mice, purchased from 
Charles River (Someren, Netherlands), were subjected 
to bleomycin-induced pulmonary fibrosis as described 
in our previous study [14]. In detail, bleomycin (Sigma, 
St-Louis) was administered intranasally (1 mg/kg) 
under anesthesia. Animals were instilled with 2.5 mg/kg 
P1pal-12 30 minutes before bleomycin administration and 
subsequently once daily until the end of the experiment. 
6% DMSO in saline was administered as solvent control. 
Mice were sacrificed 14 days after bleomycin instillation, 
after which one lung was taken for histology and one 
was homogenized. All procedures were performed in 
accordance with the Institutional Standards for Humane 
Care and Use of Laboratory Animals. Experiments were 
approved by the Animal Care and Use Committee of the 
Academic Medical Center Amsterdam.
Lentiviral knockdown of PAR-1
PAR-1 knock down cells were established 
as described before [34]. Briefly, PAR-1 (clone 
TRCN0000026806) and control (clone SHC004) shRNA 
in the pLKO.1-puro backbone were purchased from 
Sigma-Aldrich (St. Louis, MO; MISSION shRNA library). 
Lentiviral production and subsequent cell transduction 
was performed using standard protocols [32]. shRNA 
transduced NIH3T3 cells were selected in the presence of 
5 μg/ml puromycin for 72 h. 
Cell viability assays
Cells were seeded in 96-well plates at a 
concentration of 5000 cells/well, after which cell viability 
was determined using a 3-(4,5-dimethylthiazol- 2-yl)-
2,5-diphenyltetrazolium (MTT) assay at 12 and 24 hours 
according to routine procedures.
Calcium assay
Calcium signaling responses were analyzed using 
the Fluo-4 Direct™ Calcium Assay Kit (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions. 
Cells were challenged with thrombin. Ca2+ flux was 
monitored for the indicated time points on a Bio-Tek HT 
Multi-Detection Microplate Reader (Winooski, United 
States).
Wound scratch assay
Scratch assays were performed essentially as 
described before [14]. Briefly, fibroblasts were seeded in 
six-well plates in DMEM supplemented with 10% FCS. 
After the cells formed a confluent monolayer, a scratch 
was created in the center of the monolayer by a sterile 
p200 pipette tip. Next, medium was removed and cells 
were washed with serum-free medium to remove floating 
debris. The cells were subsequently incubated for 18 hours 
with serum-free medium (negative control), RAW264.7 
conditioned medium or RAW264.7 conditioned medium 
containing 10 μM of each TGF-β receptor inhibitor or 10 
μM P1pal-12. When indicated, cells were pre-incubated 
with 10 μM P1pal-12 for 30 minutes before scratching. 
The ability of cells to close the wound was assessed by 
comparing the 0- and 18-hour phase-contrast micrographs 
of 6 marked points along the wounded area. The 
percentage of non-recovered wound area was calculated 
by dividing the non-recovered area after 18 hours by the 
initial area at 0 hour as previously described.
Western blot
Fibroblasts were seeded in 12-well plates in 
DMEM supplemented with 10% FCS. Next, medium 
was removed and cells were washed with serum-free 
medium. After serum starvation for 4 hours, the cells 
were incubated with serum-free medium (negative 
control) or RAW264.7 conditioned medium with or 
without 10 μM of each TGF-β receptor inhibitor or 10 
μM P1pal-12. When indicated, cells were pre-incubated 
with 10 μM P1pal-12 for 30 minutes. Twenty four 
hours later, cells were lysed in Laemmli lysis buffer and 
Western blots were performed as described before [14]. 
In brief, protein samples were separated by 10% SDS 
gel electrophoresis and transferred to a PVDF membrane 
(Millipore, Billerica, MA). Membranes were blocked for 
1 hour in 4% milk in TBST and incubated overnight with 
monoclonal antibodies against a-SMA (1:1000, Santa 
Cruz, CA), GAPDH (1:1000, Santa Cruz, CA), collagen 
(1:800, SouthernBiotech, AL) or p-SMAD2 (1:1000, Cell 
Signaling Technology, Boston, MA) at 4°C. All secondary 
antibodies were horseradish peroxidase (HRP)-conjugated 
from DakoCytomation (Glostrup, Denmark) and diluted 
according to the manufacturer’s instructions. Blots 
were imaged using Lumilight plus ECL substrate from 
Roche (Almere, The Netherlands) on an ImageQuant 




Serum starved Raw264.7 cells (1×105 CellTrace 
CFSE labeled for real-time analysis or 2×104 unlabeled 
for analysis by microscopy) were transferred to 8 µm 
pore-size Cell Culture inserts coated with 0.1% (w/v) 
collagen. The cells were incubated in serum-free medium 
with or without thrombin, and the inserts were incubated 
at 37°C for 10 hours in serum-free medium or MLE-15 
conditioned medium as chemoattractant. For real time 
analysis, fluorescence values representing the number 
of cells on the bottom side of the insert were read on 
a BioTek plate reader at 485/528 nm (BioTek®, Bad 
Friedrichshall, Germany). For microscopic analysis, 
cells on the upper side of the transwell membrane were 
removed with a cotton swab after which the inserts were 
fixed and stained in a crystal violet solution as described 
before [34]. The membranes were subsequently mounted 
on a glass slide, and migrated cells were counted by light 
microscopy. Cells were counted in five different fields 
using a 200× magnification. 
Immunohistological analysis
Four-μm sections were deparaffinized and 
rehydrated. Endogenous peroxidase activity was 




 in methanol. F4/80 staining 
was performed using an anti-F4/80 antibody (1:500, 24 
hour at 4°C, AbD Serotec, Kidlington, UK). A horseradish 
peroxidase-conjugated polymer detection system 
(ImmunoLogic, Duiven, the Netherlands) was applied for 
visualization, using an appropriate secondary antibody 
and diaminobenzidine (DAB) staining. Slides were 
photographed with a microscope equipped with a digital 
camera (Leica CTR500). Pictures of F4/80 stainings were 
taken to cover the entirety of all sections. Color intensity 
of stained areas was analyzed semi-quantitatively with 
ImageJ and expressed as percentage of the surface area 
essentially as described before [35]. 
TGF-β ELISA
TGF-β1 was measured with the Mouse TGF-β1 
DuoSet kit (R&D systems, UK) as suggested by the 
manufacturer. 
Quantitative real-time PCR
Total RNA was isolated from cells with 
TriPure (Roche, Almere, Netherlands) following 
the manufacturer’s recommendations. q-PCR was 
performed with SYBR Green PCR master Kit (Roche) 
using the following primers: Thrombin (FII): forward 
5’-GGCAACCTAGAGCGTGAGT-3’ and reverse 
5’-TAGCACAGCGACCTTCCAGA-3’; FX: forward 
5’-GACCAAATATAAAGACGGCGAC-3’ and reverse 
5’-TCCGAACAAAGAGCTCACAGT-3’; Granzyme 
K: forward 5’-TGAGCCCATGAAGCAGACAT-3’ 
and reverse 5’- TGGCATTTGGTCCCATCTCT-3’; 
Matrix metalloproteinases(MMP)-1: forward 
5’-TTACGGCTCATGAACTGGGT-3’ and reverse 
5’- GTTGGCTGGATGGGATTTGG-3’; MMP-13: 
forward 5’-AACATCCATCCCGTGACCTT-3’ and 
reverse 5’-TTCTCAAAGTGAACCGCAGC-3’; KLK-
1: forward 5’-CCCACAACCTGAGGATGACT-3’ and 
reverse 5’-GCTTGAGGTTCACACACTGG-3’; KLK-
4: forward 5’- ATCTCTCAGTGGCGTCAGAG-3’ and 
reverse 5’-CTGCCCACACTTTCCTTGTC-3’; KLK-
6: forward 5’-TGGTGTCATTCCCCTCCAAC-3’ and 
reverse 5’-CCATGAACCACCTTCTCCTGT-3’. GAPDH: 
forward 5’-CTCATGACCACAGTCCATGC-3’ and 
reverse 5’-CACATTGGGGGTAGGAACAC -3’; TBP: 
forward 5’-GGAGAATCATGGACCAGAACA-3’ and 
reverse 5’-GATGGGAATTCCAGGAGTCA-3’.
The qPCR data were normalized to the average of 
the housekeeping genes GAPDH and TBP.
Statistics
Statistical analyses were conducted using GraphPad 
Prism version 5.00, (GraphPad software, San Diego, 
CA, USA). Data were expressed as means ± SEM. 
Comparisons between two conditions were analyzed 
using two tailed unpaired t-tests when the data where 
normally distributed, otherwise Mann-Whitney analysis 
was performed. P values of less than 0.05 were considered 
as significant.
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